Article
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
British journal of clinical pharmacology - 1 Jul 2007
Dickinson Gemma L, Lennard Martin S, Tucker Geoffrey T, Rostami-Hodjegan Amin
Abstract excerpt
AIM: To assess the power of in vivo studies needed to discern the effect of genotype on pharmacokinetics (PK) and pharmacodynamics (PD) using CYP2C9 and (S)-warfarin as an example. METHODS: Information on the in vitro metabolism of (S)-warfarin and genetic variation in CYP2C9 was incorporated into a mechanistic population-based PK-PD model. The influence of study design on the ability to detect significant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.